Shohta Ueno
Shohta Ueno represents Regeneron Pharmaceuticals in legal proceedings and manages its global disputes especially in relation to intellectual property matters in Europe and Asia.
Before joining Regeneron, Ueno worked at Allen & Overy and advised on matters with a high scientific and technological content often working with world leading experts. He advised Regeneron on asserting its patents relating to a novel platform for producing antibody therapies using transgenic mice. In that case, he had the opportunity to work with eminent scientists including a world leading immunologist from MIT and a Nobel prize winning molecular biologist. The English Court of Appeal decided in favour of Regeneron (Regeneron v Kymab [2018] EWCA Civ 671) by overturning the decision by the English High Court. In 2017, Ueno was recommended in Legal 500 for the category of pharmaceutical and biotechnology.
Ueno moved to Allen & Overy from a leading US law firm in 2014. During his time at the US law firm, he was on secondment to a leading Japanese pharmaceutical company based in Cambridge, advising the company on various IP matters. Prior to joining the legal sector, he worked for the Department of Pathology at the University of Cambridge and also obtained a PhD in Virology. During his time at Cambridge, Ueno supervised a number of medical students at Christ's College at Cambridge. His other work experiences include working for GlaxoSmithKline and Prometic Biosciences and an internship at Japan Bioindustry Association.
Ueno is bilingual in English and Japanese and his team was the 2007 winner for the Biotechnology Yes competition, defeating 64 other teams in the UK.
